New approaches to the treatment of refractory depression

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 1, 2000, Pages 26-32

  Fava, Maurizio ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; LAMOTRIGINE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PEMOLINE MAGNESIUM; PERGOLIDE MESILATE; PINDOLOL; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; PANIC; PRIORITY JOURNAL; REVIEW; SEDATION; SEROTONIN SYNDROME; TREATMENT FAILURE; TREMOR; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; BUSPIRONE; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; MORPHOLINES; PINDOLOL; SEROTONIN UPTAKE INHIBITORS; THYROXINE; TRIAZOLES; TRIIODOTHYRONINE;

EID: 0033996834     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
2. Fawcett J, Barkin RL. Efficacy issues with antidepressant. J Clin Psychiatry 1997;58(suppl 6):32-39
3. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann 1998;28:633-640
4. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
5. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;42:281-290
6. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harvard Rev Psychiatry 1999;6:322-326
7. Fredman SJ, Rosenbaum JF, Fava M, et al. How often do psychiatrists raise the dose when SSRIs do not work? In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 15-22, 1999; Washington. DC. Abstract NR128:97
8. Johnson FN. Lithium augmentation therapy. Rev Contemp Pharmacother 1991;2:1-52
9. Price LH. Pharmacologic strategies in refractory depression. In: Tasman A, Goldfinger SM, Kaufman CA, eds. American Psychiatric Press Review of Psychiatry. Vol 9. Washington, DC: American Psychiatric Press; 1990: 116-131
10. Himmelhoch JM, Detre T, Kupfer DM. et al. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 1972;155:216-220
11. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985;142:619-623
12. Fein S, Paz V, Rao N, et al. The combination of lithium carbonate and an MAOI in refractory depression. Am J Psychiatry 1988;145:249-250
13. Dinan TJ. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-301
14. Bauman P, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996;16:307-314
15. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study [see comments]. Am J Psychiatry 1994;151:1372-1374
16. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80-86
17. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989;146:278
18. Aronson R, Offman HJ, Joffe T, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996;53:842-848
19. Jacobsen FM. A possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
20. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54: 269-271
21. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin reuptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997;87(suppl 4):534-537
22. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998;18:465-469
23. Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 1998;13:83-86
24. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-668
25. Perez V, Gilaberte I, Faries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
26. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89
27. Zanardi R, Artigas F, Franchini L. et al. How long should pindolol be assodated with paroxetine to improve the antidepressant response. J Clin Psychopharmacol 1997;17:446-450
28. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155: 1346-1351
29. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):16-23, 24-25
30. Berman RM, Darrell AM, Miller ML, et al. Effects of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind placebo-controlled trial. Am J Psychiatry 1997;154:37-43
31. Moreno F, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997;58:437-439
32. Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999;56: 375-379
33. John L, Perreault M, Tao T, et al. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 1997;29:287-289
34. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone [letter]. J Clin Psychiatry 1997;58:89
35. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993;29:207-211
36. Michelson D, Bancroft J, Targum S, et al. Buspirone and amantadine treatment of SSRI associated sexual dysfunction: a randomised, placebo-controlled trial. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998; Las Croabas, Puerto Rico
37. Sporn J, Fava M, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar disorder. Presented at the 39th New Clinical Drug Evaluation Unit Meeting; June 1-4, 1999: Boca Raton. Fla
38. Wharton R, Perel J, Dayton P, et al. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;127: 1619-1625
39. Fawcett J, Kravitz HM, Zajecka MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
40. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76
41. Bader G, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol 1998;18:255-256
42. Marshall RD, Randall D, Johannet CM, et al. Bupropion and sertraline combination treatment in refractory depression. J Psychopharmacol 1995; 9:284-286
43. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996;16:80-81
44. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
45. Spier SA. Use of bupropion with SSRIs and venlafaxine. Depress Anxiety 1998;7:73-75
46. Young SJ. Panic associated with combining fluoxetine and bupropion [letter]. J Clin Psychiatry 1996;57:177-178
47. Labbate LA, Grimes JB, Hines A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 1997;9:241-245
48. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-115
49. Bhatara VS, Magnus RD, Paul KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998;32:432-436
50. Benazzi F. Venlafaxine-fluoxetine interaction. J Clin Psychopharmacol 1999;19:96-98
51. Fava M, Rosenbaum JF. Pharmacotherapy and somatic therapies. In: Beckham EE, Leber WR, eds. Handbook of Depression. New York, NY: Guilford Publications; 1995:280-301
52. Fava M, Mulroy R, Alpert JE, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154:1760-1762
53. Bondolfi O, Chautems C, Rochat B, et al. Nonresponse to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996;128:421-425
54. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-491
55. Price LH, Carpenter LL, Zelijko J, et al. Mirtazapine augmentation in the treatment of refractory depression. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology: Dec 14-18, 1998; Las Croabas. Puerto Rico
56. Sussman N. Augmentation strategies in depression. Presented at the 10th Annual US Psychiatric and Mental Health Congress Conference and Exhibition: Nov 21-24, 1997; Orlando, Fla
57. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
58. Nelson JC. Combined drug treatments: pros and cons. Presented at the 152nd annual meeting of the American Psychiatric Association: May 15-22, 1999: Washington, DC
59. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
60. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1991;3:209-214
61. Zajecka JM, Geffries SH, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
62. Harkin A, Kelly JP, McNamara M, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999;364:123-132
63. Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry 1998;59(suppl 5):65-69
64. Shelton R, Tollefson G, Tohen M, et al. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 1998; Boca Raton, Fla
65. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor. Psychopharmacol Bull 1987;23:169-172
66. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149:195-198
67. Kocsis J, Thase ME, Keller MB, et al. Double-blind crossover antidepressant study: sertraline vs imipramine. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1995; San Juan, Puerto Rico
68. Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resislant chronic fatigue syndrome. Biol Psychiatry 1992;32: 834-838
69. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
70. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
71. De Montigny C, Debonnel G, Bergeron R, et al. Venlafaxine in treatment-resistant depression: an open-label multicenter study. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12. 1995; San Juan, Puerto Rico
72. Thase ME, Zajecka J, Kornstein SG, et al. Nefazodone treatment of patients with poor response to SSRIs. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998; Las Croabas, Puerto Rico
73. Feiger A, Kiev A, Shrivastava RK. et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
74. Fava M, Dunner D, Griest J, et al. An open-label study with mirtazapine in depressed patients who are SSRI treatment failures. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 19, 1999; Washington, DC. Abstract NR431:186
75. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8-10